Algorithm and method for evaluating late endpoint endpoints in prostate cancer

摘要

The present disclosure is based on multiple gene expression based genomic prostate scoring (prostate) in patients with prostate cancer, such as clinical relapse (CR), biochemical recurrence (BCR), distant metastasis (MES) and prostate cancer death (PCD) risk It relates to the use of (GPS) algorithms.In some embodiments, the results of the GPS are determined for these patients so as to help determine the treatment policy of low and moderate risk prostate cancer patients.